Medigene AG

General information
Medigene AG
Lochhamer Str. 11
Planegg
82152 Martinsried, Bavaria
Germany

Contact person: Anna Niedl, IR / Corporate Communications
Company main phone: +49 (89) 2000330
Company main fax:  +49 (89) 2000332920
Website:  www.medigene.com
Year founded:1994
Source of foundation:Spin-off from company
Name of foundation source:Munich Gene Center
No. of employees: Worldwide:  64
At this location:  64
Corporate description / mission:
Medigene AG is a publicly listed biotechnology company, which is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with a focus on T cell receptor-modified T cells (TCR-Ts) and associated projects currently in pre-clinical and clinical development.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2000
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Cell therapy
  • Gene therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase I:1
Phase II:3
Description of products:
T cells are at the center of Medigene’s therapeutic approaches. With the aid of Medigene’s immunotherapies the patient’s own defense mechanisms are activated, and T cells harnessed in the battle against cancer. Medigene’s therapies arm the patient’s own T cells with tumor-specific T cell receptors (TCRs). The resulting TCR-Ts should thereby be able to detect and efficiently kill cancer cells.
This approach to immunotherapy aims to overcome the patient’s tolerance to cancer cells and tumor-induced immunosuppression by activating the patient’s T cells outside the body, genetically modifying them with tumor-specific TCRs and finally multiplying them. In this way, large numbers of specific T cells are made available to patients to fight the cancer within a short period of time.
Special IP situation:
Research and development and the associated know-how is secured in 54 granted and 98 outstanding patents (2020: 47 granted and 58 outstanding patents) and forms the foundation of all our activities.
Technology used:
- TCR-T
- PD1-41BB switch receptor
- Dendritc cells
Financing details
Fiscal year (end of) 2021
Revenues:EUR 10.40M
R&D expenses:EUR 12.80M
Cash:EUR 22.40M
No. of shares:24
Market cap. / valuation:EUR 70.50M
Money raised to date:EUR 61.41M
Financing details:
Data as of 1 August 2022.
Collaborations & Clients
Partnering strategy / collaborations:
- 2seventy bio, Inc.
- BioNTech SE
- Cytovant
X